Haris Dzubur
Corneal and Contact Management · Oak Lawn, ILNPI 1760725923
Payments from drug & device makers
Across 490 payments — averaging $52.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyevance Pharmaceuticals LLC$16K
- Novartis$1K
- Mallinckrodt Hospital Products Inc.$989
- Harrow Eye, LLC$941
- Bausch & Lomb Americas Inc.$925
- Tarsus Pharmaceuticals, Inc.$747
- plus $5K from 30 others
What the payments were for
- Consulting fees$2,2509%
- Speaking & faculty fees$9,73337%
- Travel & lodging$2,0528%
- Food & beverage$11,78245%
- Education$760%
- Gifts$170%
- Entertainment$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyevance Pharmaceuticals LLC | 129 | $15,715 |
| Novartis | 80 | $1,245 |
| Mallinckrodt Hospital Products Inc. | 22 | $989 |
| Harrow Eye, LLC | 26 | $941 |
| Bausch & Lomb Americas Inc. | 37 | $925 |
| Tarsus Pharmaceuticals, Inc. | 16 | $747 |
| Dompe US, Inc. | 26 | $682 |
| Coopervision Inc. | 9 | $641 |
| Alcon | 20 | $622 |
| Sun Pharmaceutical Industries Inc. | 25 | $561 |
| Biotissue Holdings Inc. | 10 | $425 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $389 |
| Sight Sciences, Inc. | 14 | $374 |
| Oyster Point Pharma, Inc. | 18 | $339 |
| Rxsight Inc | 4 | $267 |
| Oasis Medical, Inc. | 3 | $227 |
| LKC Technologies, Inc. | 3 | $184 |
| AbbVie(2 entities) | 7 | $124 |
| Topcon Healthcare, Inc. | 2 | $98 |
| Optos, Inc. | 2 | $53 |
| Johnson & Johnson Vision Care, Inc. | 2 | $44 |
| Glaukos Corporation | 1 | $42 |
| Thea Pharma Inc. | 2 | $39 |
| Vyera Pharmaceuticals, LLC | 3 | $38 |
| Beaver-visitec International, Inc. | 1 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| Menicon America Inc | 1 | $31 |
| Akorn Operating Company LLC | 1 | $21 |
| Santen Inc. | 1 | $21 |
| Akorn, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Tearlab Corp | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
| Synergeyes, Inc. | 1 | $10 |
| Quidel Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tobradex ST$7,599
- Flarex$3,958
- Zerviate$2,603
- ACTHAR$470
- INFUSE$386
- VEVYE$375
- MiSight Contact Lens$250
- XDEMVY$237
- OASIS TEARS$177
- TOTAL30$146
- BIOTRUE ONE DAY$143
- Prokera$116
- AmnioGraft$116
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$108
- MyDay Contact Lens$106
- Precision 1$103
How this compares
$25,962 in reported general payments places this provider in the 90th percentile of 34 corneal and contact management providers in Illinois.
See all corneal and contact management providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 26 | $49,254 |
| XiidraLifitegrast | 36 | $24,248 |
| VevyeCyclosporine | 17 | $15,463 |
| Latanoprost | 24 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $747 | $49,25426 claims |
| Bausch & Lomb Americas Inc.Xiidra | $925 | $24,24836 claims |
| Harrow Eye, LLCVevye | $941 | $15,46317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 34 corneal and contact management providers in Illinois.
Other corneal and contact management in Oak Lawn
- Harold DavisOak Lawn$151
- Jennifer WongChicago$37K
- Robert SteinmetzChicago$34K
- Tiffany AndrzejewskiHighland Park$29K
- Paul VeltingMorton$5K
- Cesar LauChicago$3K
- Ryan NguyenChicago$3K
- Matthew McGeeChicago$3K
- Alan KarikomiChicago$3K
- Dawn WickizerAlgonquin$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.